Your search history is turned on.
Date: April 29, 2024 Jurisdictions: Alberta, Ontario
Create participation fee form FORM 13-502F1 CLASS 1 AND CLASS 3B REPORTING ISSUERS PARTICIPATION FEE MANAGEMENT CERTIFICATION I, LEVIN, Gadi, an officer of the reporting issuer noted below have examined this Form 13-502F1 (the Form) being submitted hereunder to the Ontario Securities Commission and certify that to my knowledge, having exercised reasonable d...
Date: April 29, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Form 52-109FV1 Certification of Annual Filings Venture Issuer Basic Certificate I, Alan Rootenberg, Chief Financial Officer of Vaxil Bio Ltd, certify the following: 1. Review: I have reviewed the annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorporated by reference in the AIF (tog...
Create participation fee form Note: [01 Mar 2017] The following is a consolidation of 13-501F1. It incorporates amendments to this document that came into effect on March 1, 2017. This consolidation is provided for your convenience and should not be relied on as authoritative. FORM 13-501F1 CLASS 1 REPORTING ISSUERS AND CLASS 3B REPORTING ISSUERS PARTICIPATI...
Form 52-109FV1 Certification of Annual Filings Venture Issuer Basic Certificate I, Gadi Levin, Chief Executive Officer of Vaxil Bio Ltd., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorporated by referenc...
Microsoft Word - Vaxil FS Dec 2023 v11gv FINAL VAXIL BIO LTD. CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022 VAXIL BIO LTD. CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED DECEMBER 31, 2023 AND 2022 INDEX Page ...
1 Vaxil Bio Ltd. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS For the year ended December 31, 2023 The following is a discussion and analysis of the activities, consolidated results of operations and financial condition of Vaxil Bio Ltd. (Vaxil, we, our, us, or the Company) for the ye...
Date: January 10, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Vaxil Bio Enters Into Letter of Intent With Copper Bullet Mines in Respect of a Proposed Reverse Takeover Not for distribution to United States newswire services or for release publication, distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States NESS-ZIONA, Israel, Jan. 10, 2024 -- Vaxil Bio Ltd. (Vaxil or the Company) (TSXV:VXL) and Copper Bullet ...
Date: November 13, 2023 Jurisdictions: Alberta, British Columbia, Ontario
FORM 52-109FV2 FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Alan Rootenberg, Chief Financial Officer of Vaxil Bio Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Vaxil Bio Ltd. (the issuer) for the interim period ended Septemb...
Microsoft Word - VXL_Q3 2023 CEO cert FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE I, Gadi Levin, Chief Executive Officer of Vaxil Bio Ltd., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Vaxil Bio Ltd. (the issuer) for the interim pe...
1 VAXIL BIO LTD. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS For the three and nine month periods ended September 30, 2023 The following Managements Discussion and Analysis (MD&A) for Vaxil Bio Ltd. (Vaxil) (with its subsidiaries, the "Company") has been prepared as of November 13, 2023 and ...